Alternative buffer systems in biopharmaceutical formulations and their effect on protein stability

Area of Science:

• Biopharmaceutical formulation development
• Protein stability and characterization
• Buffer system optimization

Background:

• Biopharmaceutical formulation aims to enhance drug stability, including chemical, conformational, colloidal, and interfacial aspects.
• Buffer composition is critical for protein stability, but conventional buffers like histidine and phosphate may not suit all monoclonal antibodies (mAbs).
• Exploring alternative buffer systems is essential for optimizing biopharmaceutical formulations.

Purpose of the Study:

• To investigate the impact of various alternative buffer systems on the stability of seven different monoclonal antibodies (mAbs).
• To evaluate the influence of ionic strength, buffer concentration, mAb concentration, and stress conditions on protein stability.
• To identify optimal buffer systems for enhancing protein stability under different stress conditions.

Main Methods:

• Tested seven different mAbs across various buffer systems, ionic strengths, concentrations, and stress conditions (temperature, freeze-thaw, light).
• Assessed protein stability by quantifying soluble aggregate formation using size exclusion chromatography.
• Analyzed the effects of specific excipients like arginine and lysine on protein stability in different buffer combinations.

Main Results:

• Protein instability was observed in bis-TRIS/glucuronate buffer under temperature stress at low mAb concentrations.
• Freeze-thaw stress significantly increased aggregate formation, with arginine/citrate buffers demonstrating high efficacy in preserving stability.
• Arginine addition stabilized histidine buffers against temperature stress, while lysine caused destabilization. Histidine/citrate buffer proved optimal for high mAb concentrations under temperature and light stress.

Conclusions:

• Alternative buffer systems, such as arginine/citrate and histidine/citrate, can offer superior protein stabilization compared to conventional buffers for mAbs.
• The choice of buffer system is highly dependent on the specific mAb, concentration, and stress conditions encountered.
• Biopharmaceutical formulation development should consider a broader range of buffer options beyond traditional choices to ensure optimal drug product performance.